12 Best Buy-the-Dip Stocks to Invest In Now
In this article, we will take a look at some of the best buy-the-dip stocks that are currently offering attractive upside potential. On June 5, CNBC reported that U.S.
Posts Tagged ‘Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds
In this article, we will take a look at some of the best mid-cap healthcare stocks that are being highly favored by hedge funds.
10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
7 Best Small-Cap Healthcare Stocks to Buy According to Hedge Funds
In this article, we will look at the best small-cap healthcare stocks to buy according to hedge funds.
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising low-cost stocks to buy now.
11 Most Promising Low-Cost Stocks to Buy Now
On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the state of equity markets, assessing which stocks are growing fast...
Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment
On January 30, Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) resubmitted its Biologics License Application (BLA) to the U.S.
13 Best Revenue Growth Stocks to Buy Right Now
Speaking to CNBC on January 13, Ari Wald, Head of Technical Analysis at Oppenheimer, said U.S.
Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the promising stocks to buy under $50.
10 Promising Stocks to Buy Under $50
On January 7, Jay Woods, Chief Market Strategist at Freedom Capital Markets, joined CNBC to state that stocks are broadening beyond tech, with materials, defense, transports, ...
12 Stocks that Will Bounce Back According to Wall Street Analysts
On January 5, Reuters reported that many analysts believe global investors will actively look for opportunities in undervalued areas of the financial markets in 2026.
Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall
Ultragenyx rebounded by 15.52 percent on Tuesday to close at $22.78 apiece as investors resorted to bargain-hunting following the previous day’s steep 46 percent fall, dragged...
Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts?
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks to buy according to Wall Street analysts.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks with huge upside potential.
10 Most Promising Stocks with Huge Upside Potential
On November 25, Matt Powers, managing partner of Powers Advisory Group, joined CNBC's 'Squawk Box' to discuss what to make of recent volatility and why he believes that value ...
Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT
The analyst’s bullish stance stemmed from Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) strong financial position, alongside its pivotal late-stage pipeline.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth...
Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks with high potential.
14 Biotech Stocks with High Potential
On October 1, Evan Seigerman, head of healthcare research at BMO Capital Markets, appeared on CNBC’s “The Exchange” to talk about what the future may be like for healthcare...
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best strong buy stocks to invest in according to Wall Street.
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate...
Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission
Ultragenyx Pharmaceutical Inc.
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
Ultragenyx Pharmaceutical (RARE) Gets a Complete Response Letter for UX111
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 11 Best All-Time Low Stocks to Buy According to Analysts. On July 12, Ultragenyx Pharmaceutical Inc.
11 Best All-Time Low Stocks to Buy According to Analysts
On July 19, Jordan Jackson, global market strategist at JPMorgan Asset Management, joined CNBC Television to talk about what’s next for the market as companies are reporting...
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts.
12 Best 52-Week Low Stocks to Buy According to Analysts
On July 15, the Consumer Price Index data revealed that core inflation increased by 0.2% on the month; however, the annual rate of 2.9% remains within the estimated range.
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light
Ultragenyx fell by 26.05 percent week-on-week as investor sentiment was largely dragged down by the Food and Drug Administration’s (FDA) rejection of its biologics license application...
Ultragenyx’s GTX-102 Receives FDA Breakthrough Therapy Designation for Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks according to Wall Street analysts.
16 Most Promising Stocks According to Wall Street Analysts
On July 3, Scott Wren, Wells Fargo senior global market strategist, and Adam Crisafulli, Vital Knowledge founder, joined 'Closing Bell Overtime' on CNBC to talk about the current...
Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential
Wall Street is overflowing with data. If companies are not releasing their earnings, economic data flows almost daily.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
5 NASDAQ Stocks with Biggest Upside
Rivian Automotive, Inc. (NASDAQ:RIVN) manufactures and develops category-defining electric vehicles (EVs) and related accessories.
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential.
15 Best Strong Buy Stocks To Invest In
In this piece, we will take a look at the 15 best strong buy stocks to invest in.
13 Most Promising Future Stocks To Buy According To Hedge Funds
In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds.
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
10 Oversold Healthcare Stocks to Buy
In this article, we will take a look at the 10 healthcare stocks to buy.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
5 Oversold Biotech Stocks to Buy
In this article, we will take a look at the 5 oversold biotech stocks to buy.
10 Best Economic Recovery Stocks to Buy
In this piece, we will take a look at the ten best economic recovery stocks to buy.
Hedge Fund Resource Center
